Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

NCT05175508 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

180

Enrollment

OTHER

Sponsor class

Conditions

AML
MDS
Old Age; Debility
Hematologic Cancer

Interventions

DRUG: Azacitidine
DRUG: all trans retinoic acid

Sponsor

The First Affiliated Hospital of Soochow University